Trait: male reproductive organ cancer

Experimental Factor Ontology (EFO) Information
Identifier EFO_0007355
Description A primary or metastatic malignant neoplasm involving the male reproductive system. Representative examples include prostate carcinoma, penile carcinoma, testicular seminoma, and testicular embryonal carcinoma. [NCIT: C8561]
Trait category
Cancer
Synonyms 26 synonyms
  • Genital Neoplasms, Male
  • cancer of male reproductive organ
  • male genital cancer
  • male reproductive organ cancer
  • male reproductive system neoplasm
  • malignant Male reproductive system neoplasm
  • malignant Male reproductive system tumor
  • malignant male reproductive organ neoplasm
  • malignant neoplasm of Male reproductive system
  • malignant neoplasm of male genital organ
  • malignant neoplasm of male genital organ or tract
  • malignant neoplasm of male genital organ, NOS
  • malignant neoplasm of male genital organ, site unspecified
  • malignant neoplasm of male genital organ, unspecified (disorder)
  • malignant neoplasm of male genital organs
  • malignant neoplasm of male genital organs (disorder)
  • malignant neoplasm of male reproductive organ
  • malignant neoplasm of the Male reproductive system
  • malignant tumor of Male reproductive system
  • malignant tumor of male Reproductive system
  • malignant tumor of male genital organ
  • malignant tumor of male genital organ (disorder)
  • malignant tumor of male reproductive system
  • malignant tumor of the Male reproductive system
  • neoplasm of male genital organ
  • tumor of male Reproductive system
Mapped term(s) 10 mapped terms
  • DOID:3856
  • ICD10:C60-C63
  • ICD10:C63.9
  • ICD9:187.8
  • ICD9:187.9
  • MESH:D005834
  • MONDO:0005836
  • MSH:D005834
  • NCIT:C8561
  • SCTID:363515000
Child trait(s) 2 child traits

Associated Polygenic Score(s)

Note: This table shows all PGS for "male reproductive organ cancer" and any child terms of this trait in the EFO hierarchy by default.
Polygenic Score (PGS) ID PGS Name PGS Publication (PGP) ID Reported Trait Mapped Trait(s) (Ontology) Number of Variants PGS Scoring File (FTP Link)
PGS000030 PrCa PGP000019 Schumacher FR et al. Nat Genet (2018) Prostate cancer prostate carcinoma 147 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000030/ScoringFiles/PGS000030.txt.gz
PGS000044 PrCa66 PGP000031 Pashayan N et al. Br J Cancer (2015) Prostate cancer prostate carcinoma 66 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000044/ScoringFiles/PGS000044.txt.gz
PGS000049 PRS103_PrCa PGP000034 Lecarpentier J et al. J Clin Oncol (2017) Prostate Cancer prostate carcinoma 103 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000049/ScoringFiles/PGS000049.txt.gz
PGS000067 PCa_PHS PGP000047 Seibert TM et al. BMJ (2018) Prostate cancer prostate carcinoma 54 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000067/ScoringFiles/PGS000067.txt.gz
PGS000084 CC_Prostate PGP000050 Graff RE et al. bioRxiv (2020) Pre Prostate cancer prostate carcinoma 161 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000084/ScoringFiles/PGS000084.txt.gz
PGS000086 CC_Testis PGP000050 Graff RE et al. bioRxiv (2020) Pre Testicular cancer testicular carcinoma
Testicular Germ Cell Tumor
52 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000086/ScoringFiles/PGS000086.txt.gz
PGS000160 cGRS_Prostate PGP000075 Shi Z et al. Cancer Med (2019) Prostate cancer prostate carcinoma 79 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000160/ScoringFiles/PGS000160.txt.gz
PGS000333 PRS_PC PGP000100 Mars N et al. Nat Med (2020) Prostate cancer prostate carcinoma 6,606,785 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000333/ScoringFiles/PGS000333.txt.gz
PGS000348 PRS_PrCa PGP000113 Black MH et al. Prostate (2020) Prostate cancer prostate carcinoma 72 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000348/ScoringFiles/PGS000348.txt.gz - Check Terms/Licenses
PGS000565 PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 21 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/PGS000565.txt.gz
PGS000566 PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,111,494 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/PGS000566.txt.gz
PGS000567 PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 78 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/PGS000567.txt.gz
PGS000568 PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,401 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/PGS000568.txt.gz
PGS000569 PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 49 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/PGS000569.txt.gz
PGS000570 PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,111,493 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/PGS000570.txt.gz
PGS000571 PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 100 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/PGS000571.txt.gz
PGS000572 PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,809 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/PGS000572.txt.gz
PGS000573 PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 31 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/PGS000573.txt.gz
PGS000574 PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,111,493 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/PGS000574.txt.gz
PGS000575 PRSWEB_PHECODE185_C61_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 47 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/PGS000575.txt.gz
PGS000576 PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 905 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/PGS000576.txt.gz
PGS000577 PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 117 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/PGS000577.txt.gz
PGS000578 PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 117 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000578/ScoringFiles/PGS000578.txt.gz
PGS000579 PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 122 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/PGS000579.txt.gz
PGS000580 PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 118 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000580/ScoringFiles/PGS000580.txt.gz
PGS000581 PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 377 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/PGS000581.txt.gz
PGS000582 PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 377 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000582/ScoringFiles/PGS000582.txt.gz
PGS000583 PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,119,311 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/PGS000583.txt.gz
PGS000584 PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,120,596 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000584/ScoringFiles/PGS000584.txt.gz
PGS000585 PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,301 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/PGS000585.txt.gz
PGS000586 PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,023 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000586/ScoringFiles/PGS000586.txt.gz
PGS000587 PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 26,418 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/PGS000587.txt.gz
PGS000588 PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 178,259 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000588/ScoringFiles/PGS000588.txt.gz
PGS000589 PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 42 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/PGS000589.txt.gz
PGS000590 PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,119,236 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/PGS000590.txt.gz
PGS000591 PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 80 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/PGS000591.txt.gz
PGS000592 PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of prostate prostate carcinoma 1,334 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/PGS000592.txt.gz
PGS000593 PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of other male genital organs male reproductive organ cancer 45 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000593/ScoringFiles/PGS000593.txt.gz
PGS000594 PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Cancer of other male genital organs male reproductive organ cancer 97 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000594/ScoringFiles/PGS000594.txt.gz
PGS000595 PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 9 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000595/ScoringFiles/PGS000595.txt.gz
PGS000596 PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 5 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000596/ScoringFiles/PGS000596.txt.gz
PGS000597 PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 771 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000597/ScoringFiles/PGS000597.txt.gz
PGS000598 PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 6 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000598/ScoringFiles/PGS000598.txt.gz
PGS000599 PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 31 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000599/ScoringFiles/PGS000599.txt.gz
PGS000600 PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 250 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000600/ScoringFiles/PGS000600.txt.gz
PGS000601 PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 40 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000601/ScoringFiles/PGS000601.txt.gz
PGS000602 PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 40 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000602/ScoringFiles/PGS000602.txt.gz
PGS000603 PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 22 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000603/ScoringFiles/PGS000603.txt.gz
PGS000604 PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608 PGP000118 Fritsche LG et al. Am J Hum Genet (2020) Malignant neoplasm of testis testicular carcinoma 44 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000604/ScoringFiles/PGS000604.txt.gz
PGS000662 GRS.PCa.269 PGP000122 Conti DV et al. Nat Genet (2021) Prostate Cancer prostate carcinoma 269 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000662/ScoringFiles/PGS000662.txt.gz
PGS000714 PRS55_PC PGP000130 Sipeky C et al. Sci Rep (2020) Prostate cancer prostate carcinoma 55 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000714/ScoringFiles/PGS000714.txt.gz
PGS000719 PRS_Prostate PGP000135 Jia G et al. JNCI Cancer Spectr (2020) Prostate cancer prostate carcinoma 134 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000719/ScoringFiles/PGS000719.txt.gz
PGS000733 PHS46+African PGP000139 Karunamuni RA et al. Int J Cancer (2020) Prostate cancer prostate carcinoma 49 http://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000733/ScoringFiles/PGS000733.txt.gz

PGS Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID)
Evaluated Score PGS Sample Set ID
(PSS ID)
Performance Source Trait PGS Effect Sizes
(per SD change)
PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000061 PGS000030 (PrCa) PSS000041 PGP000019 Schumacher FR et al. (2018) Reported Trait: Prostate cancer OR: 1.86 [1.83, 1.89] Top 7 Genetic PCs, country Samples were also part of the variant association
PPM000204 PGS000084 (CC_Prostate) PSS000123 PGP000050 Graff RE et al. (2020) Pre Reported Trait: Prostate cancer OR: 1.44 [1.41, 1.47] Genotyping reagent kit (GERA cohort only), genotyping array (UK Biobank only), age, 10 PCs. Results from meta-analysis of GERA and UKB
PPM000206 PGS000086 (CC_Testis) PSS000125 PGP000050 Graff RE et al. (2020) Pre Reported Trait: Testicular cancer OR: 2.29 [2.13, 2.47] Genotyping array, age, 10 PCs.
PPM001674 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 4.42 [4.16, 4.67] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001257 PGS000572 (PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.537 [1.433, 1.649]
β: 0.43 (0.0358)
AUROC: 0.616 [0.597, 0.636] Nagelkerke's Pseudo-R²: 0.0418
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 4.03 [2.59, 6.28]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608
PPM000987 PGS000348 (PRS_PrCa) PSS000502 PGP000113 Black MH et al. (2020) Reported Trait: Prostate cancer in men with a family history of prostate cancer OR: 1.9 [1.53, 2.4] Age
PPM000986 PGS000348 (PRS_PrCa) PSS000501 PGP000113 Black MH et al. (2020) Reported Trait: Prostate cancer AUROC: 0.64 Age
PPM000985 PGS000348 (PRS_PrCa) PSS000501 PGP000113 Black MH et al. (2020) Reported Trait: Prostate cancer OR: 1.72 [1.59, 1.88] AUROC: 0.64 [0.62, 0.66]
PPM000183 PGS000067 (PCa_PHS) PSS000105 PGP000047 Seibert TM et al. (2018) Reported Trait: aggressive prostate cancer (age at onset) z-test (p-value) < 1e-16
PPM000105 PGS000044 (PrCa66) PSS000069 PGP000032 Pashayan N et al. (2015) Ext. Reported Trait: aggressive prostate cancer (Gleason score ⩾7) OR (above vs. below 50th percentile of PRS): 1.56 [1.15, 2.1]
PPM000182 PGS000067 (PCa_PHS) PSS000105 PGP000047 Seibert TM et al. (2018) Reported Trait: aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.9 [2.4, 3.4]
PPM000184 PGS000067 (PCa_PHS) PSS000106 PGP000047 Seibert TM et al. (2018) Reported Trait: any prostate cancer HR (Hazard ratio; top 2% vs. average risk): 2.5 [2.2, 2.8]
PPM000185 PGS000067 (PCa_PHS) PSS000106 PGP000047 Seibert TM et al. (2018) Reported Trait: any prostate cancer (age at onset) z-test (p-value) < 1e-16
PPM000187 PGS000067 (PCa_PHS) PSS000107 PGP000047 Seibert TM et al. (2018) Reported Trait: very aggressive prostate cancer (age at onset) z-test (p-value) < 1e-11
PPM001675 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 2% vs. middle 40%): 2.1 [1.99, 2.21] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001676 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 2% vs. middle 40%): 3.67 [3.48, 3.87] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001677 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR bottom 20% vs. middle 40%): 0.65 [0.63, 0.67] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001678 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR bottom 20% vs. middle 40%): 0.51 [0.49, 0.52] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM000393 PGS000067 (PCa_PHS) PSS000221 PGP000058 Huynh-Le M et al. (2019) Ext. Pre Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 2.4 [2.3, 2.6] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000392 PGS000067 (PCa_PHS) PSS000222 PGP000058 Huynh-Le M et al. (2019) Ext. Pre Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.2 [4.8, 5.6] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000391 PGS000067 (PCa_PHS) PSS000223 PGP000058 Huynh-Le M et al. (2019) Ext. Pre Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.6 [5.2, 6.0] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000390 PGS000067 (PCa_PHS) PSS000220 PGP000058 Huynh-Le M et al. (2019) Ext. Pre Reported Trait: Age of aggressive prostate cancer onset Hazard Ratio (HR; top 20% vs. rest): 5.9 [5.5, 6.3] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001679 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 2.21 [2.04, 2.38] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000394 PGS000067 (PCa_PHS) PSS000224 PGP000058 Huynh-Le M et al. (2019) Ext. Pre Reported Trait: Age of prostate cancer death Hazard Ratio (HR; top 20% vs. rest): 5.7 [4.6, 7.0] Association between PHS and age-at-onset p-value < 10e-16. Only SNPs directly genotyped on the OncoArray genotyping array were considered. 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001680 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 20% vs. bottom 20%): 4.71 [4.38, 5.05] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001682 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 2% vs. middle 40%): 3.89 [3.64, 4.13] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM001683 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (bottom 20% vs. middle 40%): 0.7 [0.68, 0.73] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM001684 PGS000733 (PHS46+African) PSS000874 PGP000139 Karunamuni RA et al. (2020) Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (bottom 20% vs. middle 40%): 0.5 [0.48, 0.52] Overlap between score development and testing samples for 3 new SNPs - 10-fold cross-validation
PPM000104 PGS000044 (PrCa66) PSS000068 PGP000031 Pashayan N et al. (2015) Reported Trait: Elevated serum prostate-specific antigen (PSA) levels OR (per 1-point increase in PRS): 1.23 [1.1, 1.37] cancer stage, Gleason score
PPM000123 PGS000049 (PRS103_PrCa) PSS000075 PGP000034 Lecarpentier J et al. (2017) Reported Trait: Prostate cancer in male carriers of BRCA1/2 mutations OR: 1.56 [1.35, 1.81] AUROC: 0.62 [0.58, 0.66] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM000124 PGS000049 (PRS103_PrCa) PSS000077 PGP000034 Lecarpentier J et al. (2017) Reported Trait: Low prostate cancer aggressiveness (Gleason score < 7) OR: 1.44 [1.1, 1.87] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM000125 PGS000049 (PRS103_PrCa) PSS000076 PGP000034 Lecarpentier J et al. (2017) Reported Trait: High prostate cancer aggressiveness (Gleason score ≥ 7) OR: 1.67 [1.37, 2.04] 3 PCs of ancestry, age at breast or prostate cancer for patient-cases and age at interview for controls, mutation status of BRCA1 or BRCA2
PPM001681 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of clinically significant prostate cancer Hazard Ratio (top 2% vs. middle 40%): 1.91 [1.79, 2.04] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).
PPM000900 PGS000333 (PRS_PC) PSS000447 PGP000100 Mars N et al. (2020) Reported Trait: Incident prostate cancer C-index: 0.866 age, family history, history of benign prostate hyperplasia, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000895 PGS000333 (PRS_PC) PSS000447 PGP000100 Mars N et al. (2020) Reported Trait: Incident prostate cancer C-index: 0.857 age, genotyping array/batch, 10 ancestry PCs 10-year risk
PPM000186 PGS000067 (PCa_PHS) PSS000107 PGP000047 Seibert TM et al. (2018) Reported Trait: very aggressive prostate cancer HR (Hazard ratio; top 2% vs. average risk): 3.0 [2.2, 4.0]
PPM000491 PGS000160 (cGRS_Prostate) PSS000280 PGP000075 Shi Z et al. (2019) Reported Trait: Prostate cancer Odds Ratio (OR; high vs. average risk groups): 1.73 [1.38, 2.17]
PPM000480 PGS000160 (cGRS_Prostate) PSS000280 PGP000075 Shi Z et al. (2019) Reported Trait: Prostate cancer Mean realative risk: 1.3 [1.21, 1.38]
Wilcoxon test (case vs. control) p-value: 2.07e-18
PPM001273 PGS000588 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 2.127 [2.043, 2.215]
β: 0.755 (0.0206)
AUROC: 0.699 [0.69, 0.71] Nagelkerke's Pseudo-R²: 0.0943
Brier score: 0.0794
Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.85, 7.14]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_UKB_20200608
PPM001258 PGS000573 (PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.603 [1.495, 1.718]
β: 0.472 (0.0355)
AUROC: 0.622 [0.603, 0.641] Nagelkerke's Pseudo-R²: 0.0497
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 2.93 [1.83, 4.7]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608
PPM001260 PGS000575 (PRSWEB_PHECODE185_C61_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.577 [1.47, 1.692]
β: 0.456 (0.0359)
AUROC: 0.619 [0.601, 0.637] Nagelkerke's Pseudo-R²: 0.0456
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 3.1 [1.96, 4.92]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PT_MGI_20200608
PPM001264 PGS000579 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.747 [1.626, 1.876]
β: 0.558 (0.0364)
AUROC: 0.646 [0.627, 0.664] Nagelkerke's Pseudo-R²: 0.0675
Brier score: 0.147
Odds Ratio (OR, top 1% vs. Rest): 3.53 [2.26, 5.51]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608
PPM001267 PGS000582 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.957 [1.882, 2.035]
β: 0.671 (0.0201)
AUROC: 0.681 [0.671, 0.692] Nagelkerke's Pseudo-R²: 0.0776
Brier score: 0.0803
Odds Ratio (OR, top 1% vs. Rest): 4.85 [3.95, 5.95]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_UKB_20200608
PPM001270 PGS000585 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.907 [1.771, 2.053]
β: 0.645 (0.0378)
AUROC: 0.67 [0.652, 0.688] Nagelkerke's Pseudo-R²: 0.0837
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 3.3 [2.06, 5.29]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608
PPM001276 PGS000591 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.608 [1.498, 1.725]
β: 0.475 (0.0359)
AUROC: 0.627 [0.608, 0.645] Nagelkerke's Pseudo-R²: 0.051
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 3.18 [2.01, 5.02]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608
PPM001279 PGS000594 (PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608) PSS000554 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of other male genital organs OR: 1.227 [1.029, 1.464]
β: 0.205 (0.0899)
AUROC: 0.558 [0.506, 0.606] Nagelkerke's Pseudo-R²: 0.00729
Brier score: 0.083
Odds Ratio (OR, top 1% vs. Rest): 1.04 [0.183, 5.95]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_PT_MGI_20200608
PPM001282 PGS000597 (PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.667 [1.296, 2.143]
β: 0.511 (0.128)
AUROC: 0.656 [0.593, 0.717] Nagelkerke's Pseudo-R²: 0.0487
Brier score: 0.084
Odds Ratio (OR, top 1% vs. Rest): 2.72 [0.568, 13.1]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_LASSOSUM_MGI_20200608
PPM001285 PGS000600 (PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.619 [1.267, 2.067]
β: 0.482 (0.125)
AUROC: 0.636 [0.565, 0.698] Nagelkerke's Pseudo-R²: 0.046
Brier score: 0.0839
Odds Ratio (OR, top 1% vs. Rest): 6.35 [1.81, 22.3]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_LASSOSUM_MGI_20200608
PPM001288 PGS000603 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.625 [1.27, 2.079]
β: 0.485 (0.126)
AUROC: 0.625 [0.557, 0.693] Nagelkerke's Pseudo-R²: 0.044
Brier score: 0.084
Odds Ratio (OR, top 1% vs. Rest): 6.05 [1.73, 21.2]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_MGI_20200608
PPM000988 PGS000348 (PRS_PrCa) PSS000503 PGP000113 Black MH et al. (2020) Reported Trait: Prostate cancer in men with no family history of prostate cancer OR: 1.65 [1.49, 1.84] Age
PPM001261 PGS000576 (PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.489 [1.39, 1.596]
β: 0.398 (0.0353)
AUROC: 0.607 [0.589, 0.627] Nagelkerke's Pseudo-R²: 0.0358
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 2.46 [1.5, 4.01]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608
PPM001250 PGS000565 (PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.434 [1.336, 1.54]
β: 0.361 (0.0363)
AUROC: 0.596 [0.579, 0.615] Nagelkerke's Pseudo-R²: 0.0271
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 2.39 [1.41, 4.03]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608
PPM001251 PGS000566 (PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.393 [1.3, 1.493]
β: 0.332 (0.0352)
AUROC: 0.591 [0.573, 0.609] Nagelkerke's Pseudo-R²: 0.0245
Brier score: 0.152
Odds Ratio (OR, top 1% vs. Rest): 2.85 [1.76, 4.62]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608
PPM001252 PGS000567 (PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.505 [1.404, 1.613]
β: 0.409 (0.0354)
AUROC: 0.608 [0.59, 0.628] Nagelkerke's Pseudo-R²: 0.0379
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 3.17 [1.98, 5.06]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608
PPM001253 PGS000568 (PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.426 [1.332, 1.527]
β: 0.355 (0.035)
AUROC: 0.595 [0.577, 0.614] Nagelkerke's Pseudo-R²: 0.0281
Brier score: 0.151
Odds Ratio (OR, top 1% vs. Rest): 1.53 [0.88, 2.66]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608
PPM001254 PGS000569 (PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.643 [1.531, 1.763]
β: 0.496 (0.036)
AUROC: 0.63 [0.613, 0.648] Nagelkerke's Pseudo-R²: 0.0543
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 2.86 [1.79, 4.57]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608
PPM001256 PGS000571 (PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.67 [1.555, 1.793]
β: 0.513 (0.0363)
AUROC: 0.634 [0.617, 0.653] Nagelkerke's Pseudo-R²: 0.0583
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 2.96 [1.85, 4.74]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608
PPM001263 PGS000578 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.746 [1.681, 1.813]
β: 0.557 (0.0192)
AUROC: 0.653 [0.642, 0.662] Nagelkerke's Pseudo-R²: 0.0565
Brier score: 0.0813
Odds Ratio (OR, top 1% vs. Rest): 4.31 [3.48, 5.33]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_UKB_20200608
PPM001265 PGS000580 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.748 [1.684, 1.815]
β: 0.559 (0.0192)
AUROC: 0.653 [0.643, 0.663] Nagelkerke's Pseudo-R²: 0.0568
Brier score: 0.0813
Odds Ratio (OR, top 1% vs. Rest): 4.34 [3.51, 5.37]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_UKB_20200608
PPM001266 PGS000581 (PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.79 [1.665, 1.925]
β: 0.582 (0.0371)
AUROC: 0.651 [0.634, 0.669] Nagelkerke's Pseudo-R²: 0.071
Brier score: 0.146
Odds Ratio (OR, top 1% vs. Rest): 4.44 [2.87, 6.87]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608
PPM001268 PGS000583 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.929 [1.79, 2.078]
β: 0.657 (0.038)
AUROC: 0.668 [0.651, 0.687] Nagelkerke's Pseudo-R²: 0.0874
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 3.61 [2.28, 5.72]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608
PPM001269 PGS000584 (PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 2.173 [2.087, 2.263]
β: 0.776 (0.0206)
AUROC: 0.705 [0.695, 0.715] Nagelkerke's Pseudo-R²: 0.1
Brier score: 0.0791
Odds Ratio (OR, top 1% vs. Rest): 5.58 [4.58, 6.78]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_UKB_20200608
PPM001271 PGS000586 (PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608) PSS000573 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 2.018 [1.94, 2.1]
β: 0.702 (0.0203)
AUROC: 0.687 [0.678, 0.698] Nagelkerke's Pseudo-R²: 0.0837
Brier score: 0.0799
Odds Ratio (OR, top 1% vs. Rest): 5.88 [4.84, 7.13]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_PT_UKB_20200608
PPM001272 PGS000587 (PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.906 [1.771, 2.051]
β: 0.645 (0.0375)
AUROC: 0.665 [0.647, 0.684] Nagelkerke's Pseudo-R²: 0.0861
Brier score: 0.145
Odds Ratio (OR, top 1% vs. Rest): 4.92 [3.21, 7.55]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608
PPM001274 PGS000589 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.63 [1.52, 1.748]
β: 0.489 (0.0356)
AUROC: 0.63 [0.612, 0.648] Nagelkerke's Pseudo-R²: 0.0532
Brier score: 0.148
Odds Ratio (OR, top 1% vs. Rest): 3.14 [1.99, 4.96]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608
PPM001275 PGS000590 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.516 [1.415, 1.624]
β: 0.416 (0.0353)
AUROC: 0.614 [0.595, 0.633] Nagelkerke's Pseudo-R²: 0.0395
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.32 [1.42, 3.78]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608
PPM001277 PGS000592 (PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.537 [1.433, 1.648]
β: 0.43 (0.0357)
AUROC: 0.616 [0.598, 0.635] Nagelkerke's Pseudo-R²: 0.0408
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.55 [1.55, 4.2]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608
PPM001278 PGS000593 (PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608) PSS000554 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of other male genital organs OR: 1.193 [1.002, 1.419]
β: 0.176 (0.0887)
AUROC: 0.551 [0.5, 0.6] Nagelkerke's Pseudo-R²: 0.00553
Brier score: 0.0831
Odds Ratio (OR, top 1% vs. Rest): 1.01 [0.177, 5.76]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187_C3-MALE-GENITAL_P_5e-08_MGI_20200608
PPM001280 PGS000595 (PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.713 [1.33, 2.206]
β: 0.538 (0.129)
AUROC: 0.658 [0.594, 0.719] Nagelkerke's Pseudo-R²: 0.0543
Brier score: 0.0838
Odds Ratio (OR, top 1% vs. Rest): 2.64 [0.535, 13.0]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_P_5e-08_MGI_20200608
PPM001281 PGS000596 (PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.68 [1.28, 2.206]
β: 0.519 (0.139)
AUROC: 0.649 [0.586, 0.714] Nagelkerke's Pseudo-R²: 0.0475
Brier score: 0.0841
Odds Ratio (OR, top 1% vs. Rest): 3.49 [0.816, 14.9]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_20001-1045_PT_MGI_20200608
PPM001283 PGS000598 (PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.639 [1.263, 2.126]
β: 0.494 (0.133)
AUROC: 0.648 [0.581, 0.712] Nagelkerke's Pseudo-R²: 0.0447
Brier score: 0.0841
Odds Ratio (OR, top 1% vs. Rest): 3.85 [0.942, 15.7]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_P_5e-08_MGI_20200608
PPM001284 PGS000599 (PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.628 [1.281, 2.069]
β: 0.487 (0.122)
AUROC: 0.637 [0.568, 0.703] Nagelkerke's Pseudo-R²: 0.0473
Brier score: 0.0844
Odds Ratio (OR, top 1% vs. Rest): 4.35 [1.08, 17.5]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_C3-TESTIS_PT_MGI_20200608
PPM001286 PGS000601 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608) PSS000553 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 1.438 [1.132, 1.827]
β: 0.363 (0.122)
AUROC: 0.598 [0.526, 0.672] Nagelkerke's Pseudo-R²: 0.0258
Brier score: 0.085
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_MGI_20200608
PPM001287 PGS000602 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608) PSS000574 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 2.055 [1.692, 2.496]
β: 0.72 (0.0993)
AUROC: 0.698 [0.656, 0.74] Nagelkerke's Pseudo-R²: 0.0839
Brier score: 0.0795
Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_P_5e-08_UKB_20200608
PPM001289 PGS000604 (PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608) PSS000574 PGP000118 Fritsche LG et al. (2020) Reported Trait: Malignant neoplasm of testis OR: 2.106 [1.729, 2.565]
β: 0.745 (0.101)
AUROC: 0.703 [0.659, 0.745] Brier score: 0.0793
Nagelkerke's Pseudo-R²: 0.0882
Odds Ratio (OR, top 1% vs. Rest): 4.6 [1.75, 12.1]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE187.2_GWAS-Catalog-r2019-05-03-X187.2_PT_UKB_20200608
PPM001259 PGS000574 (PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.506 [1.406, 1.614]
β: 0.41 (0.0352)
AUROC: 0.612 [0.593, 0.63] Nagelkerke's Pseudo-R²: 0.039
Brier score: 0.15
Odds Ratio (OR, top 1% vs. Rest): 2.09 [1.24, 3.52]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608
PPM001255 PGS000570 (PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.572 [1.465, 1.687]
β: 0.452 (0.0359)
AUROC: 0.622 [0.604, 0.639] Nagelkerke's Pseudo-R²: 0.0453
Brier score: 0.149
Odds Ratio (OR, top 1% vs. Rest): 2.66 [1.63, 4.34]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608
PPM001262 PGS000577 (PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608) PSS000552 PGP000118 Fritsche LG et al. (2020) Reported Trait: Cancer of prostate OR: 1.756 [1.634, 1.886]
β: 0.563 (0.0366)
AUROC: 0.646 [0.627, 0.665] Nagelkerke's Pseudo-R²: 0.0678
Brier score: 0.147
Odds Ratio (OR, top 1% vs. Rest): 3.57 [2.29, 5.57]
age, sex, batch PCs 1-4 Cancer PRSweb PheWAS Results: PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608
PPM001365 PGS000662 (GRS.PCa.269) PSS000596 PGP000122 Conti DV et al. (2021) Reported Trait: Prostate Cancer AUROC: 0.833 Odds ratio (OR, top 10% versus 40-60% GRS): 4.17
Overall Net Reclassification Index (NRI [%]): 59.4
Age, 10 PCs
PPM001366 PGS000662 (GRS.PCa.269) PSS000595 PGP000122 Conti DV et al. (2021) Reported Trait: Prostate Cancer AUROC: 0.679 Odds ratio (OR, top 10% versus 40-60% GRS): 3.53 Age, 10 PCs, study
PPM000890 PGS000333 (PRS_PC) PSS000446 PGP000100 Mars N et al. (2020) Reported Trait: Prostate cancer (incident and prevalent cases) HR: 1.83 [1.78, 1.9] genotyping array/batch, 10 ancestry PCs
PPM001644 PGS000719 (PRS_Prostate) PSS000860 PGP000135 Jia G et al. (2020) Reported Trait: Incident prostate cancer AUROC: 0.662 [0.655, 0.67] Genotyping array
PPM001645 PGS000719 (PRS_Prostate) PSS000860 PGP000135 Jia G et al. (2020) Reported Trait: Incident prostate cancer AUROC: 0.669 [0.661, 0.676] family history of cancer (in first-degree relatives), genotyping array
PPM001624 PGS000714 (PRS55_PC) PSS000840 PGP000130 Sipeky C et al. (2020) Reported Trait: Prostate cancer OR: 2.13 [1.9, 2.39] AUROC: 0.618 [0.6, 0.63]
PPM001625 PGS000714 (PRS55_PC) PSS000841 PGP000130 Sipeky C et al. (2020) Reported Trait: Prostate cancer (clinical cases) OR: 2.18 [1.93, 2.45] AUROC: 0.622 [0.61, 0.64]
PPM001626 PGS000714 (PRS55_PC) PSS000843 PGP000130 Sipeky C et al. (2020) Reported Trait: Prostate cancer (screening trial detected) OR: 1.92 [1.56, 2.37] AUROC: 0.597 [0.57, 0.63]
PPM001627 PGS000714 (PRS55_PC) PSS000842 PGP000130 Sipeky C et al. (2020) Reported Trait: Metastatic prostate cancer OR: 1.47 AUROC: 0.549
PPM001673 PGS000067 (PCa_PHS) PSS000874 PGP000139 Karunamuni RA et al. (2020) Ext. Reported Trait: Age at diagnosis of any prostate cancer Hazard Ratio (HR top 20% vs. bottom 20%): 2.47 [2.32, 2.62] 46 of the score's 54 SNPs were used: 24 directly genotyped, and 22 with acceptable proxies (r2>0.94).

Evaluated Samples

PGS Sample Set ID
(PSS ID)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000076
[
  • 2,012 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
PSS000077
[
  • 53 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab
PSS000554 PheCode:187; ICD9CM:186.0, 186.9, 187.1, 187.2, 187.3, 187.4, 187.5, 187.6, 187.7, 187.8, 187.9, 233.5, 233.6, 236.4, 236.5, 236.6, V10.45, V10.47, V10.48, V10.49; ICD10CM:C60, C60.0, C60.1, C60.2, C60.8, C60.9, C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92, C63, C63.0, C63.00, C63.01, C63.02, C63.1, C63.10, C63.11, C63.12, C63.2, C63.7, C63.8, C63.9, D07.4, D07.6, D07.60, D07.61, D07.69, D40, D40.0, D40.1, D40.10, D40.11, D40.12, D40.8, D40.9
[
  • 137 cases
  • , 1,353 controls
]
European MGI
PSS000123 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28010
[
  • 10,810 cases
  • , 190,706 controls
]
,
100.0 % Male samples
European GERA, UKB
PSS000553 PheCode:187.2; ICD9CM:186.0, 186.9, V10.47; ICD10CM:C62, C62.0, C62.00, C62.01, C62.02, C62.1, C62.10, C62.11, C62.12, C62.9, C62.90, C62.91, C62.92
[
  • 73 cases
  • , 682 controls
]
European MGI
PSS000125 Cancer diagnoses were obtained from reigstry data in GERA, and ICD-9/10 codes mapped to ICD-O-3 codes in UK Biobank. Cancers for this phenotype were classified using the following SEER site recode(s): 28020
[
  • 713 cases
  • , 169,967 controls
]
,
100.0 % Male samples
European UKB
PSS000502 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing.
[
  • 744 cases
  • , 295 controls
]
,
100.0 % Male samples
European
(USA, NR)
AG, JHH
PSS000501 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. NSGI controls had a minimum of 1 year clincal history available in the EHR and were exlucded if any ICD9/10 diagnosis of cancer was present at any time in the EHR. Men who tested positive for RPVs in any prostate cancer susceptibility gene were exlcuded from further analysis.
[
  • 1,972 cases
  • , 1,919 controls
]
,
100.0 % Male samples
European
(USA, NR)
AG, JHH, NSGHI
PSS000503 Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing.
[
  • 1,133 cases
  • , 1,172 controls
]
,
100.0 % Male samples
European
(USA, NR)
AG, JHH
PSS000041 For each cohort core data on disease status, age at diagnosis (age at observation or questionnaire for controls), family history of PrCa, and clinical factors for cases (for example, PSA at diagnosis and Gleason score) was extracted
[
  • 46,939 cases
  • , 27,910 controls
]
,
100.0 % Male samples
European 43 cohorts
  • APCB
  • ,CONOR
  • ,COSM
  • ,CPCS
  • ,CPS
  • ,EPIC
  • ,ERSPC
  • ,FHCRC
  • ,Gene-PARE
  • ,HPFS
  • ,HZ
  • ,IMPACT
  • ,IPO-Porto
  • ,LAAPC
  • ,Leuven
  • ,MCC-Spain
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MOFFITT_PC
  • ,PCMUS
  • ,PHS
  • ,PLCO
  • ,PRAGGA
  • ,PROCAP
  • ,PROFILE
  • ,PROGReSS_PrCa
  • ,Poland
  • ,ProMPT
  • ,ProtecT
  • ,QLD
  • ,RAPPER
  • ,SAAR
  • ,SEARCH
  • ,SFPCS
  • ,SNP_Prostate_Ghent
  • ,SPAG
  • ,STHM2
  • ,SWOG-PCPT
  • ,SWOG-SELECT
  • ,TAMPERE
  • ,TOR
  • ,UKGPCS
These samples (OncoArray) were also used in the GWAS meta-analysis
PSS000573 PheCode:185; ICD9:185, 233.4; ICD10:C61, D07.5
[
  • 3,012 cases
  • , 29,652 controls
]
European UKB
PSS000574 PheCode:187.2; ICD9:186, 186.0, 186.9; ICD10:C62.0, C62.1, C62.9
[
  • 135 cases
  • , 1,349 controls
]
European UKB
PSS000840 Cases: clinically diagnosed or screen-detected prostate cancer. Controls: free of cancer
[
  • 2,738 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000841 Cases: clinically diagnosed with prostate cancer. Controls: free of cancer.
[
  • 2,283 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000842
[
  • 191 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC, PHD
PSS000843 Cases: screen-detected prostate cancer. Controls: free of cancer.
[
  • 455 cases
  • , 2,400 controls
]
,
100.0 % Male samples
European
(Finnish)
FinRSPC
PSS000220 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 26,419 cases
  • , 30,575 controls
]
,
100.0 % Male samples
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000221 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 1,424 cases
  • , 3,013 controls
]
,
100.0 % Male samples
African unspecified Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000222 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 716 cases
  • , 1,185 controls
]
,
100.0 % Male samples
Asian unspecified Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000223 Age of onset of aggressive prostate cancer, defined by Gleason score ≥7, PSA ≥10 ng/mL, T3-T4 stage, nodal metastases, or distant metastases
[
  • 24,279 cases
  • , 26,377 controls
]
,
100.0 % Male samples
European Subset of OncoArray_APC_onset samples. Determined from genetic PCs via FastPop OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000224 Age at death due to prostate cancer.
[
  • 3,983 cases
  • , 30,575 controls
]
,
100.0 % Male samples
Mean = 70.0 years
Iqr = [63.0, 76.0] years
European, East Asian, African American or Afro-Caribbean, Oceanian, Hispanic or Latin American, South Asian, African unspecified, NR Combined analysis of multiple ancestries, including: European, East Asian, African American, Hawaiian, Hispanic American, South Asian, Black African, Black Caribbean, and Other (not specified) OncoArray_Prostate List of Cohorts available from dbGaP: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001391.v1.p1
PSS000595
[
  • 1,586 cases
  • , 1,047 controls
]
,
100.0 % Male samples
African unspecified CAUG
PSS000596
[
  • 6,852 cases
  • , 193,117 controls
]
,
100.0 % Male samples
European UKB
PSS000860 Data and diagnoses on site-specific incident cancers were provided by the National Health Service Information Centre for participants from England and Wales (follow-up through March 31, 2016) and by the NHS Central Register Scotland for participants from Scotland (follow-up through October 31, 2015). Cancers were coded by the International Classification of Diseases, Ninth Revision (ICD-9) or the International Classification of Diseases, Tenth Revision (ICD-10). Prostate=(ICD-9 = 185 or ICD-10 = C61) Median = 5.8 years
[
  • 4,430 cases
  • , 396,382 controls
]
,
46.5 % Male samples
European UKB
PSS000280 Primary tumor samples from TCGA
[
  • 421 cases
  • , 0 controls
]
,
100.0 % Male samples
Mean = 62.0 years
Sd = 7.0 years
European TCGA
PSS000280
[
  • 0 cases
  • , 6,407 controls
]
,
100.0 % Male samples
European eMERGE
PSS000105 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000105 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of aggressive prostate cancer (defined as any of Gleason score ≥7, stage T3-T4, PSA concentration ≥10 ng/mL, nodal metastasis, or distant metastasis)
[
  • 628 cases
]
,
100.0 % Male samples
Mean = 64.3 years
Iqr = [60.2, 67.5] years
European ProtecT
PSS000106 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000106 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of prostate cancer.
[
  • 1,583 cases
]
,
100.0 % Male samples
Mean = 63.4 years
Iqr = [59.0, 67.5] years
European ProtecT
PSS000107 Men screened with PSA testing, who did not receive a diagnosis of prostate cancer. 4,828 individuals,
100.0 % Male samples
Mean = 59.0 years
Iqr = [55.0, 63.0] years
European ProtecT
PSS000107 Men screened with PSA testing (3.0 ng/L or higher), who received a diagnosis of very aggressive prostate cancer (defined as any of Gleason score ≥8, stage T3-4, positive nodes, or distant metastases)
[
  • 220 cases
]
,
100.0 % Male samples
European ProtecT
PSS000874 Clinically significant cancer were any of: Gleason score ≥ 7, stage T3-T4, PSA concentration ≥ 10 ng/mL, pelvic lymph nodal metastasis or distant metastasis.
[
  • 3,031 cases
  • , 3,240 controls
]
,
100.0 % Male samples
African unspecified 18 cohorts
  • BioVu
  • ,CPDR
  • ,CeRePP
  • ,EPICAP
  • ,KARUPROSTATE
  • ,MIAMI-WFPCS
  • ,MOFFITT
  • ,NMHS
  • ,PCaP
  • ,PROtEuS
  • ,SABOR
  • ,SCCS
  • ,SCPCS
  • ,SELECT
  • ,SFPCS
  • ,SWOG-PCPT
  • ,UKGPCS
  • ,WUGS
PRACTICAL consortium
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 2,148 cases
  • , 6,648 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] years European ProtecT
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 3,157 cases
  • , 0 controls
]
,
100.0 % Male samples
Range = [50.0, 60.0] years European UKGPCS
PSS000069 Prostate cancer was classified as localised disease with tumour-node-metastasis (TNM) stage T1-2 N0 M0; and advanced disease (regional-distant) with stage T3 and above or any T N1 M1; as non-aggressive tumour, Gleason score <7, and aggressive tumour, Gleason score ⩾7. Median = 13.0 years
[
  • 1,089 cases
  • , 3,878 controls
]
,
100.0 % Male samples
Range = [55.0, 71.0] years European
(Finnish)
ERSPC
PSS000068 Prostate cancer was classified as localized disease with tumor-node-metastasis stage T2 and below and advanced disease (regional-distant) was classified as localized disease with tumor-node-metastasis stage T3 and above (low aggressive tumor, Gleason score <7; intermediate to highly aggressive tumor, Gleason score ≥7). Elevated serum prostate-specific antigen (PSA) levels were defined as ≥4 ng/ml.
[
  • 4,099 cases
  • , 960 controls
]
,
100.0 % Male samples
Range = [50.0, 69.0] years European SEARCH
PSS000446 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9.
[
  • 3,617 cases
  • , 55,509 controls
]
,
100.0 % Male samples
European
(Finnish)
FinnGen
PSS000447 National registries were used to assess disease incidence. Follow-up ended at first-ever diagnosis of the disease of interest, death or at the end of follow-up on December 31, 2018, whichever came first. Disease endpoints are defined in Table S9.
[
  • 1,172 cases
  • , 47,679 controls
]
European
(Finnish)
FinnGen
PSS000552 PheCode:185; ICD9CM:185, 233.4, V10.46; ICD10CM:C61, D07.5
[
  • 1,190 cases
  • , 4,417 controls
]
European MGI
PSS000075 Breast and prostate cancer cases were defined on the basis of age at diagnosis, whichever occurred first. If breast and prostate cancer occurred at the same time, individuals were treated as patients with breast cancer.
[
  • 212 cases
  • , 1,313 controls
]
,
100.0 % Male samples
European Self-reported European ancestry 37 cohorts
  • BCFR
  • ,BFBOCC
  • ,BRICOH
  • ,CBCS
  • ,CIMBA
  • ,CNIO
  • ,CONSIT
  • ,Chicago
  • ,DEMOKRITOS
  • ,DKFZ
  • ,EMBRACE
  • ,FCCC
  • ,G-FaST
  • ,GC-HBOC
  • ,GEMO
  • ,HCSC
  • ,HEBCS
  • ,HEBON
  • ,HUNBOCS
  • ,HVH
  • ,ICO
  • ,ILUH
  • ,IOVHBOCS
  • ,IPOBCS
  • ,MAYO
  • ,MSKCC
  • ,MUV
  • ,NCI
  • ,OCGN
  • ,OSU
  • ,OUH
  • ,PBCS
  • ,SWE-BRCA
  • ,UPENN
  • ,UPITT
  • ,VFCTG
  • ,kConFab